

GET CERTAINTY NOW AND IN THE FUTURE



TECH UPGRADE
CGM
SUBSCRIPTION



Medtronic
Further. Together

INTRODUCING THE TECH UPGRADE CGM SUBSCRIPTION FROM MEDTRONIC



In Australia you generally get access to new technology every four years to five years (via Private health insurance). But our latest technology doesn't always come in four-year cycles; and because we don't want you to wait for access to what's new, we've created a special plan. It's called a Technology Upgrade CGM Subscription.

WE'VE DESIGNED AN UPGRADE PLAN FOR PEOPLE AGED 7-20 THAT CAN ACCESS THE NDSS CGM INITIATIVE

You don't just get access to the latest in pump technology now, you will also be able to access the next generation of therapy once it is available in Australia.

With this Continuous Glucose Monitoring (CGM) subscription, you get the very latest in Medtronic insulin pump therapy with SmartGuard™ now. Our MiniMed® 640G System¹ is the first one in Australia that predicts you reaching your low-level setting 30 mins before it happens and suspends basal insulin so you can prevent hypos[^].

PROTECTING YOUR HEALTH OUTCOMES TODAY

The MiniMed 640G System¹ discreetly fits in with your lifestyle with its waterproof design and remote bolus for snacks.

Improved HbA1c²
Improved glycaemic
variability³

PROTECT- ING YOUR QUALITY OF LIFE

AGED SEVEN TO TWENTY AND CAN ACCESS THE NDSS CGM INITIAIVE?



The NDSS CGM initiative only covers Australians living with Type 1 Diabetes who are aged under 21 and meet specific criteria. If you have not trialled Medtronic CGM you need to meet with your Diabetes Educator to ensure CGM is right for you or your child. For more information go to www.ndss.com.au/cgm.

WHY DO I NEED CGM?

Our current pump requires CGM to give you full system functionality. Medtronic are committed to advancing this technology and all future generations of Medtronic diabetes therapies will need compatible CGM to realise the benefits. (The transmitter and sensors are sold separately because insulin pumps may be covered by private health insurance).



PROTECTING YOU TO STAY IN TARGET

The MiniMed 640G System¹ keeps you in target range with custom basal profiles and an in-built bolus wizard.

GET IN
TOUCH
TODAY

REGISTER FOR
A CALL BACK
[www.medtronic-
diabetes.com.au/whywait](http://www.medtronic-diabetes.com.au/whywait)

CALL
1800 777 808

AGED SEVEN TO TWENTY AND CAN ACCESS THE NDSS CGM INITIAIVE?



WHAT ARE THE COSTS?

Once you have met with your Diabetes Educator you can apply for fully subsidised CGM via the NDSS. Please make sure you ask for the Medtronic starter kit that includes the G2 Transmitter and Enlite Sensors.

- To access the Tech Upgrade CGM Subscription your child needs to turn seven before the subscription ends.
- You need to send us both your proof of health insurance covering IPT plus a photo of a receipt showing you collected a box of Enlite sensors from a pharmacy within the last six weeks.
- As well as accessing the NDSS subsidy, you will need to subscribe to the Tech Upgrade CGM Plan for one year via our eshop.
- We will charge your credit card \$200 every other month.



STYLE YOUR PUMP

THREE 'LENNY THE LION' COVERS
PLUS THREE ADDITIONAL COLOURS


- Each time your card is charged we will also ship you a different colour Silicon pump cover to fit the 600 series of pumps- so you will get six covers in total -one for each payment
- All future tech upgrades will require the use of Medtronic CGM technology - just as the MiniMed 640G does today.
- Your subscription is for the period of a year. You will receive the Tech Upgrade within six months of the end date, providing this technology is available in Australia.
- Terms and conditions apply

**GET IN TOUCH
TODAY**

CALL
1800 777 808

REGISTER FOR
A CALL BACK
[www.medtronic-
diabetes.com.au/whywait](http://www.medtronic-diabetes.com.au/whywait)

HOW SMARTGUARD™ WORKS



^SmartGuard Technology is activated when the MiniMed 640G is paired with continuous glucose monitoring *The dynamic suspend feature is based on certain criteria: sensor glucose must be within 3.9mmol/L of the low limit and predicted to be 1.1mmol/L above the low limit within 30 minutes AND the pump must not be in the refractory period. ** The dynamic resume feature is based on certain preset criteria: sensor glucose must be 1.1mmol/L above the preset low limit and predicted to be 2.2mmol/L above within 30 minutes AND insulin must have been suspended for at least 30 minutes.

MEDTRONIC BRIDGING THE GAP PROGRAM MINIMED 640G



If you don't currently own a MiniMed 640G but are interested in accessing Medtronic's next generation of therapy once it launches in Australia, you can apply for a loan pump via our 'Bridging The Gap Program'. You can loan the MiniMed 640G until either your waiting period ends or your MM640G loan is replaced with the loan of the next therapy Medtronic launches in Australia. The upgrade can only be accessed by those who have purchased one of the 'seven to 20 Tech Upgrade CGM Subscriptions'.

Upon completion of the health fund waiting period, or when your current pump is out of warranty - you will be required to return the loan pump to Medtronic. You can then use your health cover to purchase the Medtronic pump that is compatible with the Medtronic CGM you are using at that time.

For further information go to www.medtronic-diabetes.com.au and search 'Bridging the Gap'.

GET IN
TOUCH
TODAY

REGISTER FOR
A CALL BACK
[www.medtronic-
diabetes.com.au/whywait](http://www.medtronic-diabetes.com.au/whywait)

CALL
1800 777 808

REFERENCES

1. The system is inclusive of the MiniMed 640G Insulin Pump, Continuous Glucose Monitoring System (Guardian 2 Link transmitter and Enlite sensor), Contour Next LINK 2.4 blood glucose meter and Medtronic CareLink therapy management software.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. *N Engl J Med.* 1993;329:977-986.
3. Bergenstal RM1, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. *Diabetes Care.* 2011 Nov;34(11):2403-5. doi: 10.2337/dc11-1248. Epub 2011 Sep 20.

MiniMed, Guardian & CareLink are trademarks of Medtronic MiniMed, Inc.

Approval # 4680-022018

© 2018 Medtronic MiniMed, Inc. All Rights Reserved.

Medtronic

Medtronic Diabetes Australia
2 Alma Road
Macquarie Park,
New South Wales, 2113
Australia

24 Hour Global Helpline
1800 777 808

medtronic-diabetes.com.au